AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lexaria Bioscience Corp. Director's Dealing 2025

May 16, 2025

34983_dirs_2025-05-16_d3bb76fa-1086-4211-9159-aee092f10c35.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2025-05-15

Reporting Person: CHRISTOPHER RICHARD (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-15	Stock Options	$1.04	A	150000	Acquired	2030-05-15	Common Shares (150000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
common shares	50000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options	$3.92	2029-08-31	Common Shares (200000)	200000	Direct

Footnotes

F1: 50,000 options were exercisable on Feb. 28, 2025, an additional 6,818 options are exercisable every month thereafter until November 30, 2026 whereby the balance of 6,822 options will be exercisable on December 31, 2026